Please assess the completion status of the following clinical trial:

Trial Title: Investigation of Cocaine Addiction Using mGluR5 PET and fMRI

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* All participants:~  * Age 21 - 60 years~ * Provide voluntary, written, informed consent~ * Physically healthy by medical history, physical, neurological, ECG, and laboratory examinations~ * For females: non-lactating, no longer of child-bearing potential or agreeing to practice effective contraception during the study (e.g., established use of oral, injected or implanted hormonal methods of contraception; placement of an intrauterine device \[IUD\] or intrauterine system \[IUS\]; barrier methods: condom or occlusive cap \[diaphragm or cervical/vault caps\] with spermicidal foam/gel/film/cream/suppository; male partner sterilization; true abstinence when this is in line with the preferred and usual lifestyle of the subject), and a negative serum pregnancy test~* Participants with a cocaine use disorder:~  * DSM-5 criteria for moderate or severe cocaine-use disorder~ * Recent street cocaine use in excess of quantities used in the current study~ * Intravenous and/or smoked (crack/freebase) cocaine use~ * Positive urine toxicology screen for cocaine~* Healthy comparison participants:~  * Successful completion of an \[18F\]FPEB scan as part of another Yale approved protocol as a healthy control/comparison subject~Exclusion Criteria:~* All participants:~  * Any condition that, in the opinion of investigators, would prevent compliance with the study protocol~ * A history of significant medical or neurological illness (e.g., coronary artery disease, significant anemia, seizures)~ * Current use of psychotropic and/or potentially psychoactive medications~ * Physical or laboratory evidence of pregnancy~ * Meet any additional PET/MR imaging-related exclusion criteria, including:~ * Presence of MRI incompatible implants and other contraindications for MRI (e.g., pacemaker, artificial joints, non-removable body piercings, etc.)~ * Participation in other research studies involving ionizing radiation within one year of the PET scans that would cause the participant to exceed the yearly dose limits~ * History of a bleeding disorder or are currently taking anticoagulants (such as Coumadin, Heparin, Pradaxa, Xarelto).~ * Claustrophobia~ * Severe motor problems that prevent the subject from lying still for PET/MR imaging~ * Complaints of chronic pain (e.g., as the result of rheumatoid arthritis)~ * Current, past or anticipated exposure to radiation in the work place~* Participants with a cocaine use disorder:~  * Other drug use disorder (except for tobacco-use disorder)~ * Less than 1 year of cocaine use disorder~ * A DSM-5 major psychiatric diagnosis (schizophrenia, bipolar disorder, etc.) unrelated to cocaine~* Healthy comparison participants:~  * Any DSM-5 major psychiatric diagnosis (schizophrenia, bipolar disorder, etc.), except tobacco-use disorder~ * Positive drug screen

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: t

Study Arms:
- Psychiatric and Cognitive Testing (Type: ACTIVE_COMPARATOR): All participants will complete psychiatric assessment and cognitive testing.
- Cocaine Self-adminstration (Type: ACTIVE_COMPARATOR): This arm plans to assess the subjective (e.g., euphoric) and behavioral effects (e.g., self-administration) of cocaine in experienced, non-treatment seeking users of the drug in a human laboratory study of self-regulated cocaine administration.
- Positron Emission Tomography (Type: ACTIVE_COMPARATOR): All participants will complete a PET scan to assess mGluR5 receptors using \[18-F\]FPEB
- Magnetic Resonance Imaging (Type: ACTIVE_COMPARATOR): All participants will complete one MRI scan to assess brain structure and function.

Based on this trial design, predict the completion outcome and termination type (if applicable).